Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Incyte has reported positive clinical results from a 28-day Phase IIa trial of INCB18424, its orally available janus-associated kinase inhibitor, in patients with rheumatoid arthritis.
Subscribe to our email newsletter
Results from the first of four treatment groups, involving 12 treated and four placebo patients, demonstrated that the 15mg twice-daily dose of INCB18424 was well tolerated and provided ACR20/50/70/90 response rates of 75%/50%/25%/17%, respectively, with responses seen as early as one week.
These results, coupled with the ability of INCB18424 to block signaling from multiple inflammatory cytokines, suggest that INCB18424 has the potential to be more effective than currently available rheumatoid arthritis therapies, including the widely used injectable biologicals.
Three additional treatment groups involving 32 rheumatoid arthritis patients are currently being evaluated at the five and 25mg twice-daily doses and 50mg once-daily dose of INCB18424.
William Williams, vice president of exploratory development at Incyte, said: “The rapid onset of activity of INCB18424, as early as one week after the start of therapy, as well as its apparent safety and oral availability, suggest that selective inhibition of JAK 1 and 2 could be an important advancement in the treatment of rheumatoid arthritis.”